Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Oral VK2735

VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

Viking Therapeutics · Phase 2 · Completed · Enrollment 280

NCT06828055

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Placebo Assignmentn/rn/rn/rn/r
Active Assignment (Dose #1)n/rn/rn/rn/r
Active Assignment (Dose #2)n/rn/rn/rn/r
Active Assignment (Dose #3)n/rn/rn/rn/r
Active Assignment (Dose #4)n/rn/rn/rn/r
Active Assignment (Dose #5)n/rn/rn/rn/r
Active Assignment (Dose #6)n/rn/rn/rn/r

Not shown

  • Placebo Assignment: endpoint not reported
  • Active Assignment (Dose #1): endpoint not reported
  • Active Assignment (Dose #2): endpoint not reported
  • Active Assignment (Dose #3): endpoint not reported
  • Active Assignment (Dose #4): endpoint not reported
  • Active Assignment (Dose #5): endpoint not reported
  • Active Assignment (Dose #6): endpoint not reported